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ABSTRACT 
For men, over the course of a lifetime the risk of developing prostate cancer is 1 in 9. Both 
the illness itself and treatment affect quality of life in multiple aspects, including urinary 
problems, pain, and sexual dysfunction. Current clinical challenges in this field include: 
inevitable drug resistance to treatments, lack of accurate diagnostic and prognostic 
biomarkers, as well as no common chemoprevention strategies. The aim of this thesis is 
therefore to identify transcript alternations associated with drug resistance (Study I and Study 
II), to evaluate potential drug targets for prostate cancer treatment (Study III), and to estimate 
the preventive effect of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) 
against prostate cancer (Study IV). 
Castration resistance and docetaxel resistance are two significant issues that arise during 
prostate cancer disease progression. We employed next generation RNA sequencing 
technology to compare hormone-resistant (Study II) and docetaxel-resistant (Study I) vs 
respective sensitive cell lines, aiming to discover a potential drug target with the capability of 
prolonging the duration of hormone and docetaxel treatments before the cancer cells 
becoming resistant. The results showed that a variety of transcript alterations were obtained 
during resistance development, including mutations, altered gene expressions, and fusion 
transcripts. These alterations might be associated with drug resistance in prostate cancer. 
As a rationale for Study III, we hypothesized that proteins that have never been reported as 
mutated in prostate cancer might play an important role in cancer progression through their 
essential function of maintaining cellular stability in cancer cells. Upon mutation, these genes 
would induce severe cellular instability such that the cells could not survive, and these cells 
would be erased through natural selection during cancer growth. In Study III, we therefore 
evaluated a non-mutated protein in prostate cancer, GPR89A, as a potential drug target with 
possible anti-cancer function.  
Low-dose aspirin has been recommended by the U.S. Preventive Services Task Force 
(USPSTF) to prevent cardiovascular disease and colorectal cancer. However, results 
published in scientific studies are controversial regarding prostate cancer. In Study IV, we 
assessed whether maintenance use of aspirin or other NSAIDs could reduce the risk of 
prostate cancer. Based on data from the Swedish Cancer Register, the Swedish Prescribed 
Drug Register and the Swedish Causes of Death Register (2005-2012), we conducted a 
nationwide cohort study and found a protective effect of aspirin and other NSAIDs against 
prostate cancer, especially after long-term intake. 
In sum, this thesis identified or assessed alternative methods against prostate cancer through 
exploring molecular approaches to develop more effective treatment methods, and by 
attempting to reduce the prevalence of cancer cases through chemoprevention. 
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1 INTRODUCTION 
For men, prostate cancer is the most common cancer in Europe and the US, and the second 
leading cause of cancer death.[1] Adenocarcinomas which originate from prostatic epithelial 
cells, are the most common cancer subtypes (95%).[2] Prostate cancer is relatively less 
aggressive than other types of cancer. And patients have a high risk of dying from causes 
other than prostate cancer, such as cardiovascular diseases, external causes and diseases 
related to pulmonary circulation.[3]  
Prostate cancer usually exhibits no symptoms during early course and grows slowly for years 
before any indications of the disease present themselves. Later symptoms include frequent 
and urgent urination, difficulty starting and controlling urination, pain or burning during 
urination, and sexual dysfunction. The most frequent metastasis locations are the bone, lymph 
nodes and brain. Bone pain is a late-phase symptom that occurs after the cancer has 
metastasized.  
Current clinical challenges regarding prostate cancer include inevitable drug resistance to 
treatments, lack of accurate diagnostic and prognostic biomarkers, as well as no common 
chemoprevention strategies. As outlined in Figure 1, below, this thesis attempts to address a 
broad spectrum of prostate cancer issues, including its initiation, progression, metastatic 
development, and treatment resistance. The goals of this thesis are to identify transcript 
alternations associated with drug resistance (Study I and Study II), evaluate potential drug 
targets for prostate cancer treatment (Study III), and estimate the preventive effect of aspirin 
and other NSAIDs against prostate cancer (Study IV). 
 
Figure 1 Prostate cancer disease continuum and corresponding treatments, as well as the overall 
outline of the thesis. M: Metastatic. 
 12 
1.1 ETIOLOGY AND MOLECULAR BACKGROUND 
The etiology of prostate cancer remains debated, although a number of factors are commonly 
believed to be associated with elevated risk of cancer development to date, including age, 
family history, lifestyle, and race. Prostate cancer occurs mainly in older men (99.9% of 
patients are over 50 years of age).[4] A family history of prostate cancer in both an 
individual’s father and brothers increases the risk of developing the cancer by 2.3-times, as 
compared with men without a family history of prostate cancer.[5] A history of breast cancer 
in close female relatives is also significantly associated with a 1.22-fold increase in the risk of 
developing prostate cancer.[5] A higher number of relatives with prostate cancer history or 
with a history of having been diagnosed with the cancer at young age may further increase an 
individual’s risk. Lifestyle factors such as regular exercise or a diet with low calcium intake 
have been found to be linked to decreased risk in developing prostate cancer. The incidence 
and mortality rates in different ethnic groups are differ significantly.[6] 
Genetics is also suggested as a primary cause of prostate cancer. The contribution of genetic 
factors was found to constitute 58% of the risk of developing prostate cancer.[7] Genome-
wide association studies (GWAS) have found weak to modest factors (more than 90 common 
single nucleotide polymorphisms (SNPs)) contributing to the development of prostate cancer, 
which taken together are estimated to explain one third of the cancer risk.[8] Other factors 
such as epigenetics or environmental causes also contribute to susceptibility of prostate 
cancer. 
Genomic abnormalities include chromosomal loss or gain, gene amplification, mutations, and 
fusions (Figure 2). Prostate cancer has a relatively low rate of genomic alternations compared 
with other cancers, e.g., 7-15 times lower than small cell lung cancer and melanoma.[9] 
Androgen receptor (AR) is the most commonly altered gene in metastatic prostate cancer, 
which leads to resistance to hormone treatment. PTEN (Phosphatidylinositol 3,4,5-
trisphosphate 3-phosphatase and Dual-specificity Protein Phosphatase) inactivation by copy 
number loss, deletions, or mutations happens in approximately 40% of prostate cancer.[10] 
RB (Retinoblastoma) loss and p53 mutation are two other common types of genetic 
alterations in prostate cancer with 28% and 40% prevalence respectively.[11] SPOP mutation 
and SPINK1 overexpression is also common, occurring in about 10% of prostate cancer 
(SPOP, Speckle Type BTB/POZ Protein, transcriptional repression activities; SPINK1, Serine 
Peptidase Inhibitor Kazal Type 1, trypsin inhibitor).[12, 13] DNA repair pathway deficiency, 
including BRCA1 (breast-cancer–associated protein 1), BRCA2 (breast-cancer–associated 
protein 2) and ATM (ATM Serine/Threonine Kinase), was discovered in about 20% of 
prostate cancer cases, which makes PARP (Poly(ADP-Ribose) Polymerase) a potential drug 
target.  
ETS (ETS transcription factor) is a transcription factor family participating in cell 
differentiation, cell cycle, migration, proliferation, apoptosis and angiogenesis, as well as 
cancer progression. ETS family members were discovered as fusions with 5’ un-translated 
region (UTR) of TMPRSS2 (Transmembrane Protease, Serine 2) and its expressions were 
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highly up regulated as a consequence.[14] Among the ETS family, TMPRSS2-ERG (ETS-
related gene) fusion is the most common rearrangement and has been found in nearly half of 
all prostate cancer samples.[15-17] ETS fusion can be detected in high grade prostatic 
intraepithelial neoplasia (PIN) and is considered to be associated with carcinogenesis instead 
of metastasis progression.[18-20] 
 
 
Figure 2 Progression pathway and involved processes and dysregulated genes in human 
prostate cancer. (From: Molecular genetics of prostate cancer: new prospects for old challenges, 
Michael M. Shen and Cory Abate-Shen, 2010). EMT: Epithelial–Mesenchymal Transition. 
 
1.2 PREVENTION OF PROSTATE CANCER 
Cancer is the second most common cause of mortality throughout the world. Many treatment 
methods, such as surgery, radiation, and chemotherapy have been developed to manage 
cancer. However, cancer is not easy to eliminate for multiple reasons, including but not 
limited to the issues of drug resistance or lack of powerful targeting strategies. Prostate 
cancer is a heavy burden in the lives of many men. The rationale for chemoprevention of 
prostate cancer is based on its high incidence, long-term disease course, and the low quality 
of life that results from the disease. 
Cancer prevention is defined as taking action to lower the risk of developing cancer through 
healthy lifestyle choices (diet and exercise), avoiding exposure to cancer-causing substances, 
and taking vaccines or medicines (chemoprevention). Chemoprevention is a method to delay 
the onset of cancer through the intake of natural or synthetic agents. At present there are no 
common agents recommended by authorities for preventing prostate cancer, although many 
interventions have been proposed and investigated as preventive agents, including 5-α-
reductase inhibitors (5-ARIs), NSAIDs, statins, and dietary supplements.[21]  
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5-α reductase inhibitors are the most studied chemopreventive agents against prostate cancer 
to date. 5-α reductase enzyme converts testosterone to dihydrotestosterone (DHT) which 
functions in the prostate and is involved in prostate cancer progression. The observation, that 
men with low 5-α reductase activity have less prostate cancer incidence, provides the 
rationale for using 5-ARIs to prevent prostate cancer.[22] A well-designed randomized 
controlled trials (RCTs), the Prostate Cancer Prevention Trial (PCPT), was designed to 
measure the preventive effect of the selective type two 5-ARI finasteride in men who were at 
low risk for prostate cancer and older than 55 years. The results showed that finasteride arm 
illustrated a reductive prevalence compared to placebo arm. However, the risk for 
intermediate and high grade cancers in finasteride group was apparently higher than the 
control group.[23] The REduction by DUtasteride of prostate Cancer Events (REDUCE) trial 
assessed the preventive effect of dutasteride and found that dutasteride arm showed decreased 
prostate cancer incidence and no statistically significant differences of high-grade cancer.[24] 
These 5-ARIs need further investigations until it can be concluded definitively whether 
finasteride induces high-grade prostate cancer.  
Statins seem promising in the prevention of advanced prostate cancer based on a meta-
analysis, which analyzed six large RCTs and 13 observational studies. These consistent 
findings supporte the argument that statins might be essential in the prevention of high-grade 
prostate cancer. A large number of dietary supplements have also been proposed and 
measured for their preventive potential in prostate cancer. These supplement reagents include 
selenium, vitamin E, vitamin A, vitamin C, multivitamins, green tea, calcium, folic acid and 
others. The best studied dietary supplements are selenium and vitamin E. One randomized 
trial, the Selenium and Vitamin E Cancer Prevention Trial (SELECT), recruited more than 
35,000 men and assigned them randomly to four groups: selenium arm, vitamin E arm, 
selenium and vitamin E arm and placebo arm. However, the results showed no risk difference 
in incidence of prostate cancer among all arms.[25] Other dietary supplements have also been 
evaluated by observational studies and RCTs but none of them have provided adequate 
evidence and authorities have not recommend any as preventive agents against prostate 
cancer. 
1.2.1 Inflammation in prostate cancer 
Chronic inflammation is the cause of about 20% of all cancer in adults.[26, 27] Growing 
evidence finds that chronic or recurrent inflammation plays an important role in prostate 
cancer initiation, development, progression and metastasis.[28] Biopsies in several prostate 
diseases show signs of inflammation, including prostatitis, benign prostatic hyperplasia 
(BPH), prostate cancer “risk lesions” (proliferative inflammatory atrophy (PIA) and PIN), 
and prostate cancer.[29-31] Prostatic Intraepithelial Neoplasia, which presents as abnormal 
epithelial cell structure around inflammatory cells, was accepted as a prostatic 
adenocarcinoma precursor, while prostatitis and PIA were proposed but have not been widely 
accepted as precursors.[32-35] Chronic inflammation can generate PIA lesions and probably 
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develop to PIN and/or prostate cancer directly.[36, 37] The clinical trial REDUCE found that 
80% of prostate cancer patients had more or less inflammation in biopsy tissues.[38]  
Various potential sources for prostatic inflammation include, but are not limited to, urine 
reflux, dietary factors, estrogens, and direct infection (bacteria and viruses, such as human 
papillomavirus, herpes simplex virus type 2, cytomegalovirus, and human herpes virus-
8).[35] Inflammatory genes relating to prostate cancer risk have also been discovered as 
mutations or other variants, including: MSR1 (macrophage scavenger receptor 1), TLR (toll-
like receptors), MIC1 (Microneme-associated protein 1) and IL1RA (Interleukin 1 Receptor 
Antagonist).[39-42] The Cancer Prostate Sweden Study (CAPS) found a SNP in TLR4 
(11381G/C) to be associated with a 39% higher risk of early prostate cancer. However, a 
follow-up study of a North American population found eight other SNPs in TLR4 while the 
11381G/C variant did not show any association with prostate cancer. This likely indicates 
that SNPs differ among different populations.[39, 40] 
1.2.2 Aspirin/NSAIDs and prostate cancer prevention 
Nonsteroidal anti-inflammatory drugs are a family of drugs that can eliminate pain and 
reduce fevers and inflammatory responses. Most NSAIDs can reversibly inhibit 
cyclooxygenase (COX) enzyme activity on both COX-1 and COX-2.[43] Cyclooxygenase, 
namely prostaglandin-endoperoxide synthase, is an enzyme family that is responsible for 
prostanoid formation. COX-1 is constitutively expressed in many tissues,[44] and COX-2 is 
expressed during inflammation and can be induced by extracellular and intracellular stimuli, 
such as epidermal growth factor (EGF), and this induction is transient.[45-47] In prostate 
cancer, COX-2 is expressed specifically in prostate inflammatory cells, especially in PIA 
lesions.[30, 35] Aspirin, also known as acetylsalicylic acid, is unique compared to other 
NSAIDs. Aspirin is a non-selective COX inhibitor, which irreversibly inhibits both COX-1 
and COX-2 iso-enzymes.[48] Aspirin is usually taken for pain, fever, and inflammation 
treatment. Systemic use of aspirin can prevent strokes, thrombus and heart attacks, and 
cancers as well, particularly colorectal cancer.[49] 
A systematic literature review found that: some studies indicate that aspirin use might be 
associated with a reduction in prostate cancer risk,[50-63] while others found no protective 
effect.[64-72] The association between NSAIDs is still unclear due to lack of evidence. Some 
studies found intake of non-aspirin NSAIDs to be associated with decreased overall prostate 
cancer risk,[73] however all NSAIDs intake increases prostate cancer risk.[73] Another meta-
analysis showed neither adverse or beneficial effects on prostate cancer development or 
prostate cancer specific mortality, but these results were not consistent.[74] More studies 
found less consistency when measuring all NSAIDs and could not draw conclusion after 
meta-analysis.[75, 76] These conflicting findings provide further evidence that aspirin or 
non-aspirin NSAIDs may have a chemo-preventive effect against prostate cancer and need 
further epidemiological studies to evaluate their activity. 
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1.3 PROSTATE CANCER SCREENING AND DIAGNOSIS 
Prostate cancer can be found through early detection methods, including: the prostate-specific 
antigen (PSA) blood test and/or the digital rectal exam (DRE) followed by a prostate biopsy. 
In Sweden, prostate cancer incidence increased significantly after the PSA testing method 
was introduced in the 1990s, as was the case in many other Western countries. However, 
despite this the mortality rate for prostate cancer remained relatively stable. Patients with 
abnormal PSA or DRE test results receive further biopsies in order to diagnose. Currently, 
PSA testing can be regarded as an opportunistic screening of prostate cancer.[77] Some 
prostate cancer will not result in PSA level changes in the blood and only a part of high-level 
PSA patients will be diagnosed as prostate cancer. At present, the only way to know for 
certain whether a man has prostate cancer is through biopsy diagnoses. 
Prostate cancer can only be cured by radical surgery or radiation when it is still localized. 
Early diagnosis can provide the best chance at cure. However, present diagnostic and 
prognostic methods cannot satisfactorily distinguish life-threatening prostate cancer at early 
stages from the majority of non-harmful indolent tumors. The prostate-specific antigen 
screening method results in increased incidence of prostate cancer, mostly indolent prostate 
tumors. This leads to over-diagnosis and over-treatment of patients with non-harmful indolent 
tumors that can seriously affect their quality of life. An approach called “active surveillance” 
is employed in monitoring patients with low risk prostate cancer. Doctors and patients have to 
struggle over the treatment strategy: should they treat directly after diagnosis or utilize active 
surveillance until disease progresses? 
Using detection methods (PSA and DRE), prostate cancer can be diagnosed early on, but it is 
still debated whether the benefits outweigh risks. The European Randomized Study of 
Screening for Prostate Cancer (ERSPC) and the Gothenburg trial found that PSA screening 
decreased mortality from prostate cancer significantly.[78, 79] In contrast, the US Prostate, 
Lung, Colorectal, and Ovarian cancer screening trial (PLCO) found no mortality reduction 
benefit from annual PSA screening compared with opportunistic screening for prostate 
cancer.[80] An observational population-based study (UK ProtecT trial) released findings in 
October of 2016, stating that prostate cancer specific mortality shows no significant 
difference across treatments (active surveillance, surgery, or radiotherapy) after a 10-year 
follow-up, although surgery and radiotherapy reduced disease progression and 
metastases.[81] More studies are needed to address these conflicting results. 
In sum, early detection of prostate cancer is not recommended on the general population scale 
for the following reasons: 1) its clinical outcomes are not clear, 2) many prostate tumors grow 
slowly and do not affect life span, and these tests cannot determine which tumors are 
dangerous, 3) over-treatment has serious adverse effects on patients, and 4) PSA tests result 
in false-positive and false-negative detection. 
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1.4 THERAPEUTIC REGIMENS 
1.4.1 Prostate cancer disease continuum and corresponding treatments  
The clinical manifestation of prostate cancer is very heterogeneous, from harmless slow-
growing localized lesions to rapidly progressive metastatic deadly disease. The choice of 
treatment modalities depends on cancer cell aggressiveness and disease extent as classified 
using the D'Amico Classification System that based on blood PSA level, prostate biopsy 
Gleason score and Tumor Node Metastasis (TNM) clinical stage.[82] Patient age and 
comorbidity play important roles in treatment decision. Standard treatments for prostate 
cancer patients include active surveillance, radical prostatectomy, radiation therapy, hormone 
therapy, chemotherapy, and others. (Figure 1).  
Autopsy reports revealed that roughly half of all men older than 50 might harbor prostate 
cancer.[83, 84] The slow growth rate and low possibility of cancer progression make active 
surveillance or watchful waiting an alternative treatment strategy, which aim to avoid 
unnecessary treatments, through close monitoring activity. In 2013, active surveillance was 
selected as treatment for 78% of very low risk and 59% of low risk cancer patients.[85] For 
intermediate and high risk patients or for localized or locally advanced cancer, radical 
prostatectomy and curative radiation as well as hormone therapy can be offered (Figure 1). 
Surgery is a common choice for treating localized prostate cancer. The main type of surgery 
is radical prostatectomy which has possible side effects of urinary incontinence and erectile 
dysfunction. Radiation is an alternative treatment option for localized prostate cancer 
patients. The two most common types of radiation used for prostate cancer are external beam 
radiation and brachytherapy (internal radiation). 
M0 castration-resistant prostate cancer is the cancer stage in which the cancer does not 
metastasize, but cancer cells are no longer sensitive to hormone treatments. In comparison, 
M1 hormone-sensitive prostate cancer is the stage where cancer cells have already 
metastasized but are still sensitive to hormone treatments. There are fewer men diagnosed 
with M0 castration-resistant prostate cancer than those diagnosed with M1 hormone-sensitive 
prostate cancer. Treatment regimens are different for the two groups of patients: enzalutamide 
is the standard treatment for M0 castration-resistant patients, while for M1 hormone-sensitive 
prostate cancer patients, docetaxel or “abiraterone and prednisone” are the current treatment 
options [86-88] (Figure 1). 
Once metastasis develops, the disease is regarded as incurable. However, several lines of 
treatments can offer improved palliation and prolonged survival. These include conventional 
androgen deprivation treatment (ADT) (e.g. Luteinizing Hormone-Releasing Hormone 
(LHRH)-analog or antagonist), next-generation hormone treatment (abiraterone acetate and 
enzalutamide),[89-91] taxane chemotherapy (docetaxel and cabazitaxel),[92, 93] and 
radiopharmaceutical agents (e.g. Radium 223)[94] (Figure 1).  
 18 
1.4.2 Hormone treatment and castration/hormone resistance 
Hormone therapy (e.g. ADT) blocks the production or use of androgen, either by using 
orchiectomy or by drugs. Removal of the testicles (orchiectomy) has the possibility of 
decreasing the level of testosterone by 90-95% and it is permanent and irreversible. 
Luteinizing Hormone-Releasing Hormone agonists/antagonists can significantly reduce the 
secretion of the luteinizing hormone, which as a consequence suppresses the production of 
testosterone in the testes. The testosterone drop induced by LHRH agonists/antagonists (also 
called medical castration or chemical castration) has similar effects as surgical castration 
(orchiectomy). Unlike orchiectomy, the drug effect on androgen production is reversible. 
Antiandrogens can inhibit prostate cancer cell growth by competing with androgen for 
binding to androgen receptors. The production of androgens by adrenal glands and prostate 
cancer cells can be blocked through Cytochrome P450 17 (CYP17) inhibitors. Cytochrome 
P450 17 is an enzyme expressed in testicular, adrenal and prostate tumor tissues and can 
regulate testosterone production. 
Androgen deprivation treatment is the standard treatment for prostate cancer patients. Most of 
these patients respond to ADT initially. However, after 2-3 years, all patients develop 
castration resistance to ADT (castration-resistant prostate cancers (CRPC)).[95-97] When 
metastasis occurs (mCRPC), prostate cancer patients have a high risk of dying from the 
cancer. The median survival time for patients with mCRPCs is up to one and half years from 
the start of metastasis.[98]  
The most common mechanisms causing CRPC are AR-related, including: 1) AR 
amplification, 2) mutated AR induced hypersensitivity to ligand binding, 3) co-factors 
(activators and suppressors) that change AR pathways, 4) ligand independent AR activation, 
and 5) AR production inside the tumors.[99] However, the androgen signal pathway may not 
be the only driver in mCRPCs and need further studies to identify, e.g. through employing 
next generation sequencing to find more potential pathways and targets.[98, 100-103]   
Next-generation sequencing has been applied to prostate cancer to find genetic alternations in 
mCRPC, and large-scale data analysis has provided more information for identifying related 
genetic alternations in cancer progression. Sequencing on paired tumor samples before and 
after ADT initiation revealed that the WNT signaling pathway is a potential target for 
mCRPC.[104] Mutations, gene expression alternations and fusions were discovered as 
potential factors in the progression of mCRPC, e.g. AR, NCOR1 (nuclear receptor corepressor 
1), KDM3A (lysine demethylase 3A), and new gene fusion SND1-BRAF (staphylococcal 
nuclease domain-containing protein 1 - B-Raf serine/threonine-protein) etc.[105] [106] 
Sequencing of formalin-fixed paraffin-embedded (FFPE) samples may also be a feasible 
strategy to discover somatic alternations in advanced prostate cancer.[106-108] Circulating 
free DNA (cfDNA) and circulating tumor cells (CTCs) can also provide a possibility of 
identifying cancer-related genetic alterations, which would likely benefit patients by assisting 
in the development of precise personalized treatment.[109] In the near future, tissue-based 
next-generation sequencing profiling coupled with non-invasive (cfDNA- or CTC-based) 
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profiling would be a powerful alternative for patients with advanced prostate cancer and 
would assist in identifying the most promising biomarkers or treatment targets.  
1.4.3 Chemotherapy and docetaxel resistance 
Common chemotherapies for prostate cancer include docetaxel and cabazitaxel. Docetaxel is 
the first choice for chemotherapy, and cabazitaxel is additionally utilized if docetaxel does 
not function or stops working. Both drugs can bind β-tubulin, stabilize microtubule assembly, 
suppress dynamics of micro-tubules and prevent disassembly, which induces cancer cell 
death.[110, 111] Cabazitaxel is a second-line chemotherapy treatment with poor affinity for 
P-glycoprotein compared with docetaxel, which reduces the chances of docetaxel resistance. 
The median overall survival period can be extended by 3-5 months using docetaxel 
chemotherapy, while cabazitaxel can result in an additional 2.4 month improvement.[100, 
112] Clinical trials have shown that docetaxel can significantly prolong patient survival if it is 
utilized with ADT in hormone naïve metastatic prostate cancer patients.[93, 113] Clinical 
experience shows that only approximately half of all patients respond to docetaxel treatment 
from the start of the treatment, which indicates that around 50% of prostate cancer patients 
have intrinsic resistance to docetaxel. Those who benefit from docetaxel treatment initially 
acquire docetaxel resistance eventually.[114, 115] Both intrinsic and acquired resistance 
result in the failure of docetaxel treatment.  
The mechanism behind intrinsic and acquired resistance to docetaxel is not fully understood 
and there are no clinically reliable biomarkers to predict it to date. Previous research suggests 
the following mechanisms: 1) high expression/function of drug export pump proteins e.g. 
ABCB1 (ATP binding cassette subfamily B 1), ABCB4,  and ABCC1 (ATP binding cassette 
subfamily C) which could pump out docetaxel from cell plasma and decrease docetaxel 
concentration,[116] 2) mutations of the corresponding drug targets,[117] 3) inhibition of 
apoptotic pathways,[118] and 4) altered expression pattern of microtubule-associated proteins 
and tubulins.[119, 120] Next-generation sequencing of patient-derived pre- and post-
docetaxel resistance xenografts showed that SLCO1B3 (organic anion-transporting 
polypeptide, an influx transporter of docetaxel) was down regulated in resistant xenografts, 
and intratumoural docetaxel concentrations were significantly decreased after acquiring 
resistance.[121]  
1.4.4 Therapy sequence for CRPC patients 
Castration-resistant prostate cancer is a late stage of prostate cancer progression in which the 
cancer continues to grow even when testosterone is reduced to a very low level e.g. castrate 
level.[122] Metastatic CRPC is one of the major causes of death among patients with prostate 
cancer. Docetaxel was initially approved as first line chemotherapy for mCRPC patients in 
2004, and subsequent drugs approved included abiraterone, enzalutamide, cabazitaxel and 
Radium-223. The appropriate sequencing of these agents is still not optimized.  
Studies have shown that early chemotherapy could improve overall survival for patients with 
metastatic hormone-sensitive prostate cancer. Several clinical trials were designed to verify 
 20 
the role of docetaxel in metastatic hormone-sensitive prostate cancer patients, including the 
CHAARTED and the STAMPEDE studies.[87, 88, 123-125] Data showed that docetaxel 
could evaluate the effect of hormone treatment and prolong the overall survival of patients 
with metastatic hormone-sensitive prostate cancer. Radium-223 is unique in reducing 
skeletal-related events and has been found to prolong survival when utilized after docetaxel 
treatment.[126] Furthermore, studies showed that Radium-223 has the potential to be utilized 
in the early stage of prostate cancer e.g. before docetaxel.[127]  
These data collectively showed that the sequence of treatments for prostate cancer are not yet 
fixed and optimized. Adjustments could be applied in practical clinical procedures based on 
new findings of clinical trials. 
 
1.5 THE ROLE OF NON-MUTATED PROTEIN IN PROSTATE CANCER 
Genetic robustness is the ability of a biological system to maintain the persistence of a certain 
trait when facing various external and internal perturbations, such as mutation, recombination 
or environmental changes. For instance, organisms exhibit a constant phenotype despite of 
mutation accumulation to a certain extent. Genetic robustness is achieved by a combination 
of many genes that contribute to a similar function by direct or indirect connection, and vice 
versa, that compensate when perturbations occur in one of these genes (buffering system). 
Genetic robustness in cancer cells implies that moderate effects and drug resistance occur 
during treatment when it inhibits only one target (gene/protein). Robustness can be combated 
through the systematic use of multiple drugs aimed at two or more specific targets, which in 
combination could result in higher-level effects or even absolute lethality in cancers.[128]  
Two or more simultaneous gene defects can cause cell or organism death. This phenomenon 
is defined as synthetic lethality, and is a consequence of a combination of two or more gene 
deficiencies where only one of these deficiencies alone does not result in lethality.[129] 
Mutations, epigenetic alterations or functional inhibitors are effectors that could cause 
synthetic lethality. Theoretically, when one gene is inhibited by intrinsic gene mutation, if we 
target and inhibit the other gene of the synthetic gene pair (non-mutated gene), it would result 
in synthetic lethality. Based on this concept, the paradigm shifts from mutated genes to non-
mutated genes as drug targets. The most well-defined example of synthetic lethality is the 
discovery of PARP inhibitors used in BRCA mutated patients with breast cancer, ovarian 
cancers, and prostate cancer.[130, 131] Experimental data and clinical evidence have shown 
that BRCA1 or BRCA2 and PARP are synthetic lethal gene pairs involved in the DNA repair 
process. Results of clinical trials have shown that BRCA deficient patients were sensitive to 
PARP inhibitors with relatively mild side effects.[132]  
Cancer therapies today benefit patients by prolonging their lives by several months to several 
years. This relatively moderate effect is likely due to 1) only targeting one mutated 
gene/protein/pathway, while cancer cells are genetically robust and can easily evolve new 
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alterations to bypass and survive, and 2) to the fact that mutated genes are probably only 
biomarkers and not driving sources of cancer progression.  
A Catalogue of Somatic Mutations (COSMIC, http://cancer.sanger.ac.uk/cosmic) database 
retrieval shows that, in cancer tissues, prostate cancer has a relatively high non-mutation rate 
(21.2%) compared with other listed cancer types, e.g. breast (10.9%) or liver cancer (12.1%) 
and that there are higher percentage of mutated genes than non-mutated genes in most of 
cancer types except in testis cancer (Table 1).  
 
Table 1 Common mutations detected in different human cancer types among the 29,059 genes in 
total recorded in the COSMIC database. 
 
It can be hypothesized that some non-mutated proteins may play important roles in 
maintaining cancer cellular stability. Once mutated, severe cellular instability would be 
induced to the degree that cancer cells could not survive. These cells, which harbor mutated 
genes or proteins, could be erased through natural selection during cancer growth. Functional 
inhibition of these proteins using different targeting methods could be lethal to cancer cells 
but less harmful to normal cells which generally carry fewer mutations in the genome.  
Golgi pH regulator A (GPR89A) is a membrane protein that is localized in the Golgi 
apparatus and regulates its acidic pH.[133] Research shows that GPR89A might be one of the 
synthetic lethal gene partners of proto-oncogene MYC, and data shows that simultaneous 
knockdown of both genes (MYC and GPR89A) could induce lethal effects in cancer 
cells.[134]  
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1.6 RNA SEQUENCING (RNASEQ) 
Next-generation sequencing has revolutionized the field of cancer biology, including prostate 
cancer. Typical sequencing includes whole-genome sequencing, whole-transcriptome 
sequencing, whole-exome sequencing etc. Single cell sequencing, cfDNA sequencing, and 
CTC sequencing have also been used to address heterogeneity of tumor tissues. Significant 
findings have been discovered through next-generation sequencing due to its accuracy and 
lower cost. However, there are still limitations, e.g. quality of sample, sequencing 
coverage/data quality, and analysis methodology, which all affect the sequencing results.  
RNA sequencing is a method that studies the transcriptome, which can be used to discover 
expression alterations, mutations, fusions etc. Illumina is the most widely used technology for 
RNAseq, as it is sensitive and accurate. Usually, a long gene list with information of interest 
would be provided after analysis of raw data (reads in fastq file). Pathway/network analysis is 
employed to find enrichment of a specific important gene group. MetaCore, STRING, 
PANTHER, DAVID and GeneGo are popular web-based database recourses. Machine 
learning (both supervised and unsupervised methods) is used to separate sample groups (e.g. 
caner vs. normal, localized vs. metastasis) to identify genes that contribute most to the group 
separation. These genes are considered potential biomarkers or targets. A variety of these 
machine learning techniques, including Artificial Neural Networks, Bayesian Networks, 
Support Vector Machines, Random Forest and Decision Trees have been widely employed.  
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2 AIMS 
The overall aim of this thesis is to identify potential drug targets and evaluate their role in 
prostate cancer treatments, as well as to assess the preventive effect of chemo-reagents 
against prostate cancer.  
I. To identify mutations, expression alterations and fusion transcripts as potential drug 
targets in docetaxel-resistant and castration-resistant prostate cancer.  
II. To evaluate the non-mutated protein GPR89A as a potential drug target in prostate 
cancer.  
III. To access the potential preventive effect of maintenance use of aspirin/NSAIDs 
against prostate cancer based on a nationwide cohort study in Sweden. 
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3 MATERIALS AND METHODS 
3.1 EXPERIMENTAL PROCEDURES 
3.1.1 Cell culture 
LNCaP, PC3, Du145 and HEK293 cell lines were originally purchased from the American 
Type Culture Collection (ATCC). The resistant cell line Du145-R was induced and cultured 
by gradually increasing docetaxel concentrations within the culture medium. Du145-R was 
cultured in the medium without docetaxel for 30 days to generate a cell line Du145-RB 
(Table 2).[135]  
 
Table 2 Characteristics of prostate cancer cell lines utilized in this thesis. 
 
Hormone-sensitive: weather the cell line is sensitive to hormone treatment (Yes) or not (No); 
Docetaxel-sensitive: weather the cell line is sensitive to docetaxel treatment (Yes) or not (No). 
 
3.1.2 RNAseq and data analysis 
Total RNA was extracted from cell lines by using TRIzol (Invitrogen, Catalog #15596018) 
followed by phenol/chloroform extraction procedure. RNase-free DNase set (Qiagen, Catalog 
#79254) was utilized to remove DNA to avoid DNA contamination. RNA Integrity Number, 
which was selected as a reference of quality control, was analyzed using the Agilent 2100 
Bioanalyzer System. All cell lines were triplicates when sent for sequencing. Total RNA 
samples were selected by polyA and then clustered on cBot. The sequencing was performed 
by HiSeq 2000 according to the manufacturer’s instructions.  
Variant calling: Polymerase chain reaction (PCR) duplicates were removed by Picard 
(picard.sf.net) and reads were subsequently extracted from the bam file and imported into 
CLC Genomics workbench (CLC, Aarhus, Denmark). The build 37p5 was utilized as a 
human reference genome by Large Gap Read Mapping. Probabilistic Variant Detection tool 
within CLC Genomics workbench was utilized to call variants. Criteria applied during the 
variant calling procedure were: variant probability higher than 90, minimum coverage and 
ignore non-specific matches. An alternative method utilized in this thesis was Genome 
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Analysis Toolkit (GATK) best practices for RNAseq somatic mutation finding. The 
procedure, which provided step-by-step guiding for performing variant discovery analysis in 
RNA sequencing data, included base quality score recalibration, INDEL realignment, 
duplicate removal, and INDEL discovery. RNAseq fastq data was aligned to reference 
genome hg38 using STAR 2 pass and the GATK was applied to call variants. 
Analysis of differentially expressed genes: TopHat was employed to align reads to the 
reference genome. Cufflinks was utilized to assemble and obtain expression values of genes 
across genomes. The resulting data was analyzed using Cuffdiff to report the differential 
expression profile. The CummeRbund R package was utilized for the subsequent analysis and 
visualization.[136] 
Fusion detection: The ChimeraScan was employed to align the paired-end reads to the 
reference genome. Those read pairs that could not be aligned to the reference genome were 
trimmed into smaller segments and realigned. [137] 
Pathway/network and cluster analysis: Pathway and network analysis were conducted in 
online services Panther (http://www.pantherdb.org) and Thomson Reuters.[138, 139] The 
Circos online (http://mkweb.bcgsc.ca/tableviewer) was utilized to visualize fusion transcript 
distribution among chromosomes. OPLS-DA model was one function of SIMCA software 
that could be employed to find essential contributors that separated samples into different 
groups. In our project, two classes (TaxS and TaxR) were pre-set in two groups and VIP 
scores of each variables/genes were calculated and sorted based on importance.[140] 
3.1.3  PCR and quantitative PCR (qPCR) 
Total RNA was isolated and extracted by TRIzol (Invitrogen, Catalog # 15596018) following 
the manufacturer’s instructions. Reverse transcription was carried out through Cloned AMV 
First-Strand Synthesis Kit (Life Technologies, Catalog # 12328). Polymerase chain reaction 
primers for mutation validation were designed to cover mutation points. Platinum Taq DNA 
polymerase (Life Technologies, Catalog # 10966018) was utilized to amplify DNA segments. 
Sanger sequencing was conducted by Eurofins Genomics to confirm mutations found by 
RNAseq. For validation of up- or down-regulated genes, 20-32 amplifying cycles were 
selected according to gene expression level. We employed qPCR to validate fusion 
transcripts. Primers for fusion validation were ordered from Applied Biosystems (Custom 
plus TaqMan RNA Assays). Roche LightCycler480 SYBR Green I Master (Cat. No. 
04887352001) was utilized to conduct qPCR.  
3.1.4 Plasmid construction and Western blot  
DNA segments of interest were amplified by PCR and digested by restriction enzymes: Sgf I 
and Mlu I (NEB, Catalog # R0630S and Catalog # R0198S). These digested DNA segments 
were inserted into the multiple cloning sites of pCMV-AC-GFP (ORIGENE, Catalog # 
PS100010) by T4 ligase (Promega, Catalog # M180A). Constructed plasmids were 
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transfected into HEK293 cells and these cells were collected 48 hours after transfection. Anti-
TurboGFP antibody (Evrogen, Catalog # AB513) were utilized in Western blot. 
3.1.5 Gene knockdown 
SiRNAs were synthesized from GE-healthcare (using a customized Cherry pick screening 96 
well plate). The plate was stored in the fridge upon arrival and underwent no more than three 
cycles of thawing-and-freezing. Transfection reagent HiperFect was purchased from Qiagen 
(Catalog# 301705) and OptiMEM was purchased from Gibco (Catalog 31985). Both were 
used according to the manufacturer's protocol.  
3.1.6 Immunocytochemistry and immunohistochemistry 
PC3 cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.1% 
Triton™ X-100 for 30 minutes, blocked with 1% BSA for 1 hour and incubated with anti-
GPR89A primary antibody (Pierce, Cat. #PA5-33786, 1:400) for 1.5 hours at room 
temperature. Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody Alexa 
Fluor® 488 conjugate (Thermo Fisher, Product# A-11008) was diluted (1:400) in phosphate 
buffered saline containing 0.2% Bovine Serum Albumin (BSA) and incubated for 1 hour at 
room temperature for detection of the expression level of GPR89A. Formalin-fixed paraffin-
embedded tissue was sectioned and deparaffinized using Xylen. Antigen retrieval was 
conducted in a citrate buffer (pH6, water bath) and the tissue was incubated with 0.5% H2O2 
in water for 30 minutes. Anti-GPR89A (Pierce, Cat. #PA5-33786) was diluted (1:400) and 
incubated at 4 °C overnight. Avidin Biotin Complex (30 minutes) was employed to amplify 
the target antigen signal. 
3.1.7 Combination study between docetaxel and GPR89A siRNA 
Cell seeding and reverse transfection were carried out simultaneously. Docetaxel was utilized 
to treat cells 16 hours after transfection/cell seeding. Cell viability was measured 48 hours 
after docetaxel treatment. PrestoBlue (A13261) cell viability reagent was purchased from 
ThermoFisher. Synergistic effect was determined by comparing 1) the combination effect 
when docetaxel (D) and GPR89A siRNA (G) were used simultaneously to treat cells in the 
same well (“IR(D+G)”) with 2) the estimated additive effect (“IR(D)+IR(G)-IR(D)*IR(G)”) 
where IR(D) indicates the Inhibition Rate (IR) of docetaxel and IR(G) indicates the IR of 
GPR89A siRNA. If the combination effect was higher than the estimated additive effect we 
concluded that the combinatory treatment of these two reagents could cause a synergistic 
effect. If the combination effect was equal to or less than the estimated additive effect, we 
stated that the combinatory treatment of these two reagents could result in an addictive effect 
or an antagonism effect, respectively. 
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3.2 REGISTER DATA MANAGEMENT AND STATISTICAL ANALYSIS 
3.2.1 Data sources 
Sweden is famous for its nationwide, high-quality data registers. Each resident in Sweden has 
a specific identity number (person number), which makes it possible to link these national 
registers to each other. In Study IV, we utilized the Swedish Prescribed Drug Register, the 
Swedish Cancer Register and the Swedish Causes of Death Register. 
The Swedish Prescribed Drug Register was established in July 2005 and includes all drugs 
prescribed and dispensed in Sweden. Over-the-counter drugs and drugs prescribed and 
dispensed within a hospital are not included. Information from all prescriptions dispensed in 
ambulatory care is transferred monthly to the National Board of Health and Welfare, which is 
responsible for the register.[141] The register is complete for the entire Swedish population 
(patient identification data are missing for <0.3% of all items).[141] 
The Swedish Cancer Register was established in 1958 and has the registration of the type and 
date of diagnosis of all cancers in Sweden since 1961.[142] The completeness of prostate 
cancer is more than 95% when compared to records of death certificates.[143] This register 
was used to identify cancer cases among the exposed cohort and the general population. The 
Registry was also used to exclude individuals with a history of cancer before 2005. 
The Swedish Causes of Death Register was established in 1952 and was used to collect date 
of death among the exposed (maintenance use of NSAIDs) and unexposed individuals. Date 
of immigration/emigration is not available. 
3.2.2 Study design 
Study IV is a nationwide Swedish population-based cohort study used to compare the 
exposed cohort with the Swedish general population of the same age and calendar year. 
Study period: The study included individuals who were enrolled between July 1, 2005 (the 
beginning of the Swedish Prescribed Drug Registry) and December 31, 2012. The study 
followed individuals until the occurrence of any cancer, death or December 31, 2012, 
whichever occurred first.  
Exposure: Maintenance use of NSAIDs was subdivided as follows. Individuals with ≥180 
days of both categories was excluded. 
 Aspirin (B01AC06; N02BA), ≥180 days 
 Non-aspirin NSAIDs (M01A), ≥180 days 
Maintenance use was defined as a cumulative dose of at least 6 months duration during the 
study period. The total cumulative administered dosage was estimated by the Defined Daily 
Dose (DDD), which takes the potency of the drug into account as well as the prescribed 
quantity. The World Health Organisation defines DDD as the assumed average maintenance 
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dose per day for a drug used for its main indication in adults. Aspirin and NSAIDs are 
available over-the-counter in Sweden, but only in small packages and at a higher price. 
DDD per package= (items issued * amount of drug per item) / DDD 
The unexposed reference was general population in Sweden of the same age and calendar 
period. The fact that many of the individuals in this population use NSAIDs occasionally 
might to some extent dilute the identified effects, but nonetheless does not explain them.  
Outcome: The outcome was a first cancer episode according to the International 
Classification of Diseases 10th edition.  
Potential confounders: Statins have been shown to have potentially protective effects 
against prostate cancer. The concomitant use of statins (longer than an accumulated 180 days) 
during the study period was adjusted as a confounder. Age and calendar year were taken into 
account as well. 
Inclusion and exclusion criteria: Only adult men (≥ 18 years) without a previous history of 
any cancer were included, and only if they had at least 180 days of exposure to aspirin or 
other NSAIDs (as defined above).  
3.2.3 Data collection 
The following data was collected from The Swedish Prescribed Drug Register: 
 Age at index date (e.g. first dispensed prescription of aspirin or NSAIDs during study 
period) and date of birth. 
 Relevant Anatomical Therapeutic Chemical codes. 
 Dates of prescribing and dispensing. Date of dispense is considered most accurate 
since it is closer to actual use. 
 To calculate cumulative exposure, the number of prescriptions, dosage, number of 
doses, DDD were extracted from the register database. 
The Cancer Registry was used to collect all prostate cancers cases of interest, as well as 
exclude individuals with a history of cancer before 2005. Specific detailed variables collected 
during data management included:   
 Date of cancer diagnosis 
 Location of tumor and histological type 
 Age at diagnosis 
3.2.4 Statistical analysis 
The risk of developing prostate cancer was compared between the exposed cohort and 
Swedish general population of the same age by means of standardised incidence ratios (SIRs) 
and 95% confidence intervals (CIs). The SIRs were calculated by dividing the observed 
incidence rate of prostate cancer by the expected incidence rate based on the total Swedish 
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male population of the same age and calendar year.[144] Time of follow-up was from the 
dispensed date of the first prescription of aspirin/NSAIDs within the study period, until death, 
cancer or the end of study period, whichever occurred first.  
A separate analysis was performed to assess the impact of duration of treatment based on the 
cumulative dosage (based on sum of DDD) categorized as duration  (less than 1 year, 1–3 
years, 3–5 years, and longer than 5 years for aspirin, and  less than 1 year, 1–3 years, and 
longer than 3 years for NSAIDs). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  31 
4 RESULTS AND DISCUSSION 
4.1 DOCETAXEL RESISTANCE IN PROSTATE CANCER (STUDY I) 
Triplicates of the docetaxel-resistant (TaxR) cell lines Du145-R and Du145-RB, as well as 
docetaxel-sensitive (TaxS) cell line Du145, were sent for whole transcriptome RNAseq. 
Compared to the TaxS cell line, the TaxR cell lines stably acquired 42 mutations. Polymerase 
chain reaction was employed to validate the accordance between bioinformatics data analysis 
and wet-lab experiments. Data showed that all the four randomly selected mutations could be 
validated by PCR, which implied high accuracy of transcriptome sequencing and 
bioinformatics data analysis. Among these stably acquired mutations in TaxR cell lines, 
SMAD4 (Mothers Against Decapentaplegic Homolog 4) and ABCA2 (ATP-Binding Cassette 
Sub-family A Member 2), which were previously reported as associated with drug resistance 
in cancer, were also identified in the TaxR cell lines.[145-148] 
Analysis of RNAseq data reported 48, 75 and 66 fusion candidates in the Du145, Du145-R 
and Du145-RB cell lines respectively. Sixteen fusion candidates whose ChimeraScan score 
was above 5 were selected to be validated, and among them, 13 (81.25%) could be verified 
by PCR and Sanger sequencing. Of the 13 chosen validated fusion candidates, 10 were 
commonly expressed in all the three cell lines. One fusion (MYH9-EIF3D) was exclusively 
identified in the TaxR cell line and two other fusions (TAF15-AP2B1, VCL-ADK) were only 
detected in the TaxS cell line, which implies its potential association with primary or acquired 
resistance to docetaxel.  
Four fusion transcripts (MYH9-EIF3D, LDLR-RPL31P11, TAF15-AP2B1, VCL-ADK) were 
selected to be validated by qPCR and Western blot. Data showed that all the four fusions 
could be transcribed and translated in the plasmid transfected HEK293 cell line. The fusion 
transcripts were validated by qPCR in the original cell lines (Du145, Du145-R and Du145-
RB), however, these fusion proteins could not be detected in the cell lines using Western blot, 
which was possibly due to low expression. Interestingly, we found two bands in one PCR 
lane when VCL-ADK was amplified, which indicated different transcript patterns of these two 
proteins. Sanger sequencing showed that both of the fusions were VCL-ADK fusion 
transcripts, although with different fusion points within ADK.  
In total, we identified 329 up-regulated and 286 down-regulated genes whose expressions 
were altered in Du145-R as well as in Du145-RB as compared to Du145. These genes 
demonstrated stably altered expressions when the cells acquired resistance to docetaxel. The 
40 most up- or down-regulated genes in the TaxR cell lines were selected and further 
validated by PCR. Of these genes, 37 out of 40 (92.5 %) were found in accordance with the 
bioinformatics data analysis of RNA sequencing. Among the up-regulated genes, ABCB1, 
which was reported as a transporter of small molecular drugs through membranes and 
associated with drug resistance,[147] was also identified in this project. Moreover, pathway 
and network analysis reported three knots: NF-κb (Nuclear Factor Kappa B), EGR1 (Early 
Growth Response 1) and ETS, through which most of the genes with altered expression were 
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linked to the whole network. The importance of ABCB1 was further confirmed through its 
connection to these three knots in the network analysis. 
 
4.2 CASTRATION RESISTANCE IN PROSTATE CANCER (STUDY II) 
To identify acquired mutations, altered expressions, and the existence of fusion transcripts 
during the development of castration resistance, we performed whole transcriptome RNAseq 
in triplicates of two castration-resistant cell lines, PC3 and Du145, and one hormone-sensitive 
cell line LNCaP. After analysis, we identified 4397 mutations (in 2579 genes) that were 
acquired when cells became resistant to hormone treatment. Pathway analysis revealed that 
the most enriched pathway was the immune response B cell antigen receptor (BCR) pathway, 
which indicates a potential immune system related mechanism behind acquired resistance to 
hormone treatment. 
Compared to the hormone-sensitive cell line, we identified 157 down-regulated and 549 up-
regulated genes whose expressions were consistently regulated in both of the castration-
resistant cell lines. Thirty of the dysregulated genes were selected for validation by PCR. 
Results showed that 28 out of 30 could be verified, indicating a high quality of the RNA 
sequencing analysis. Furthermore, all up- or down-regulated genes (in total 706) were 
analyzed using network enrichment, which reported three dominant connection knots: GCR 
(NR3C1, Glucocorticoid Receptor), PKA-cat kinase (PRKACB, cAMP-dependent Protein 
Kinase Catalytic Subunit Beta) and protein kinase C family (PRKD1, Serine/Threonine-
Protein Kinase D1). The glucocorticoid receptor has previously been reported as associated 
with acquired resistance to ADT in prostate cancer.[149-151] Moreover, PRKACB and 
PRKD1 are involved in various cellular functions e.g. proliferation, differentiation and 
apoptosis, which implies their potential importance in cancer progression. 
We also identified 117, 48 and 60 fusions in the LNCaP, Du145 and PC3 cell lines, 
respectively. Among them, one fusion (AF086285-ATP6V1E2) was commonly detected in all 
three cell lines and six were identified exclusively in the castration-resistant cell lines. Out of 
25 selected chimeric transcripts (unique alignment positions parameter > 5), 11 top-ranked 
fusions were selected and data showed that eight of these (72.7%) could be validated by PCR. 
Among them, four chimeric transcripts (MIPOL1-DGKB, GPS2-MPP2, RERE-PIK3CD and 
TFDP1-GRK1) could only be detected in the hormone-sensitive cell line LNCaP, while the 
other three (SMAGPTFCP2, KDM5B-CR936711, SAMD8-ADK) were only detected in the 
castration-resistant cell line. These findings collectively indicate that the fusions exclusively 
expressed in the castration-sensitive or resistant cell lines respectively might be associated 
with the primary or acquired resistance to hormone treatment. However, further experimental 
validations are needed. 
Multiple molecular mechanisms are involved in the development of castration resistance, and 
the most well-defined mechanism is dysregulations of AR.  This study demonstrated that AR 
was not expressed in the two hormone-resistant cell lines, PC3 and Du145, which was in 
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agreement with findings from previous publications.[152-154] This might therefore indicate 
that the alterations acquired in the castration-resistant cell lines in this study were possibly 
AR-independent.  
 
4.3 EVALUATION OF THE NON-MUTATED PROTEIN AS A POTENTIAL DRUG 
TARGET IN PROSTATE CANCER (STUDY III) 
To assess the percentage of mutated genes in prostate cancer, a retrieval was performed in the 
COSMIC database and 22,909 genes were identified as mutated (78.8%) out of all genes 
recorded (29,059). The remaining 6150 (21.2%) genes were not reported as mutated. 
Comparing this with our RNAseq data of prostate cancer cell lines in Study I and Study II, 
we selected 17 genes which had higher mRNA expression. Among these selected genes, 
knockdown of GPR89A was associated with decreased cell viability as well as increased 
apoptosis in both PC3 and Du145 prostate cancer cell lines and therefore was selected as the 
gene of interest. 
Immunocytochemistry showed that GPR89A was expressed in cytoplasm in the prostate 
cancer cell line PC3. Immunohistochemistry in prostate cancer patient tissues indicated that 
the cancer cells within tumor areas showed a higher GPR89A expression compared to 
adjacent benign areas. 
Docetaxel is a standard treatment for metastatic prostate cancer. To evaluate the 
combinational potential between docetaxel and GPR89A siRNA, we measured the effect of 
combined treatment of docetaxel and GPR89A siRNA on PC3 cell line compared to their 
estimated additive effect. Based on concentration titration, single reagent effect of docetaxel 
at 0.3 nM and GPR89A siRNA at 5-80 nM were selected in the combination study. The 
corresponding estimated additive effect for each concentration was calculated. Combined 
treatment of docetaxel and GPR89A siRNA showed higher effect than the estimated additive 
effect, which indicated that docetaxel has a synergistic combination effect with all different 
concentrations of GPR89A siRNA ranging from 5 nM to 80 nM. 
The importance of the Golgi apparatus has become more and more evident as a potential anti-
cancer target.[155, 156] Previous studies have demonstrated the potential of Golgi-associated 
molecules as drug targets in androgen-sensitive and resistant prostate cancers.[155] Notably, 
the protein of interest GPR89A is localized in the Golgi apparatus and functions in pH 
regulation of the internal Golgi environment. This might be the mechanism of action of 
GPR89A as a potential drug target in prostate cancer. Moreover, docetaxel is an anti-mitotic 
chemotherapy functioning through microtubule stabilization, which enhances microtubule 
polymerization and affects cancer cell survival. The combination treatment of docetaxel and 
knockdown of GPR89A targets both of the essential intracellular systems and causes 
dysfunction of Golgi as well as microtubules, which might eventually result in synergistic 
effects. 
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4.4 ASPIRIN/NSAIDS AND PROSTATE CANCER PREVENTION (STUDY IV) 
The prevention effect of aspirin and non-aspirin NSAIDs was estimated by including 419,931 
aspirin users in the cohort which contributed 2,053,932 person-years, as well as 223,437 non-
aspirin NSAIDs users which contributed 1,305,848 person-years. Aspirin users were older 
and had a higher percentage of prostate cancer cases than non-aspirin NSAIDs users. Among 
aspirin users, 62.9% of men had concomitant maintenance use of statins, while only 14.7% 
non-aspirin NSAIDs users were found to have this concomitance. 
The overall SIR of aspirin users is 0.87 with 95% CI 0.85–0.88, which suggests that 
maintenance aspirin intake could protect men from prostate cancer. All age groups above 50 
showed a reduced risk of prostate cancer. The NSAIDs also showed a preventive effect 
against prostate cancer (SIR=0.87, 95% CI 0.85–0.90). Yet, the association was only 
significant in the age groups of 50–59 and 60–69 years. 
Long-term intake of aspirin (longer than five years) showed a significant protective effect 
(SIR=0.31 95% CI 0.30–0.32), while shorter duration groups indicated a lower protective 
effect. In the non-aspirin NSAIDs group, the protective effect appeared from intake of one 
year and longer, and the strongest preventive effect was found in the subgroup of those taking 
NSAIDs for more than three years (SIR = 0.58, 95% CI 0.53–0.63). 
When the cohort was separated according to the status of concomitant maintenance use of 
statins, no significant effect remained in the aspirin group without concomitant statins intake 
(SIR=0.99, 95% CI 0.96–1.02), except for after long-term exposure (SIR=0.31, 95% CI 0.29-
0.34). Maintenance use of non-aspirin NSAIDs did show a protective effect, although this 
was less pronounced when maintenance statins users were excluded (SIR = 0.92, 95% CI 
0.88–0.95). Poisson regression adjusted for age showed that statins intake reduced the risk of 
prostate cancer by 22% (IRR=0.78, 95% CI 0.75–0.81) in the aspirin group and by 20% (IRR 
= 0.80, 95% CI 0.73, 0.87) in the non-aspirin NSAIDs group, compared to non-statins users. 
These findings collectively suggest an overall protective effect of aspirin and non-aspirin 
NSAIDs against prostate cancer, especially after long-term intake. The effect of aspirin was 
higher than non-aspirin NSAIDs, however, this influence could be explained to some extent 
by concomitant statins intake among 63% of aspirin users.  
This is a nationwide cohort study based on the Swedish population. The register databases of 
the entire Swedish population provided accurate and valid data sources, especially the 
Prescribed Drug Register, which decreased recall bias and misclassification of exposures. A 
minor limitation of the drug register is that it does not include drugs purchased over-the-
counter. However, prescribed drugs in Sweden are subsidized and cheaper, so we therefore 
assumed that the majority of drugs were purchased through a prescription. We assessed drug 
usage by average DDD per package, which might induce an over- or under-estimation of the 
accurate daily use. 
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In this project, statins were found to be associated with a reduced risk of prostate cancer, and 
the protective effect of aspirin was diluted by concomitant maintenance use of statins. 
Unfortunately, we could not measure the interaction between aspirin/non-aspirin NSAIDs 
and statins due to the study design. Some confounders e.g. obesity, diet, and socio-economic 
and ethno-geographic risk factors were not included in this analysis. However, Sweden is a 
fairly small and developed country, and there is a relatively low level of differences in socio-
economic status and ethnicity for the majority of inhabitants. 
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5 PERSPECTIVES 
Current clinical challenges in prostate cancer includes: 1) inevitable drug resistance to a 
variety of treatments, 2) lack of accurate diagnostic and prognostic biomarkers, as well as 3) 
no common chemoprevention strategies. This thesis is multi-dimensional and addressed 
different aspects of prostate cancer research areas, from castration resistance to docetaxel 
resistance to cancer prevention, by identifying transcript alternations associated with drug 
resistance and estimating the prevention effect of aspirin and non-aspirin NSAIDs against 
prostate cancer. 
Genomic alteration is one of the hallmarks of human malignancies, including mutations, 
altered gene expressions and fusion transcripts. We identified a variety of transcript 
alterations that were possibly associated with either hormonal resistance or docetaxel 
resistance. However, these genomic/transcriptomic alterations occur during cancer 
progression and their roles are still controversial: Are they driving sources or only 
concomitant phenomenon during cancer progression? Additionally, the percentage of 
mutated genes in cancers showed that only about 20% of all genes have never been reported 
as mutated in prostate cancer. This might imply that the majority of these mutated genes are 
passengers not drivers of cancer progression. Our findings in Study III suggest a new research 
area, which is to treat cancer by targeting non-mutated genes that might play an essential role 
in maintaining the stability of cancer cells. 
There is a saying that “prevention is better than a cure”.  However, to date this can only be 
applied in a minority of cancers e.g. cervical cancer prevention by HPV vaccines and breast 
cancer prevention by surgically removing breast tissues. Recently, aspirin was recommended 
in the US to prevent colorectal cancer. For other cancer types, including prostate cancer, there 
are no commonly known preventive strategies. Study IV elucidates the potential of aspirin 
and non-aspirin NSAIDs as preventive reagents in prostate cancer. However, further studies 
are still needed to accumulate evidence either in support of this approach or to identify new 
protecting reagents. 
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